Melody A Cobleigh
Overview
Explore the profile of Melody A Cobleigh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
2456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Brann A, Cobleigh M, Okwuosa T
JAMA Oncol
. 2016 Jun;
2(9):1123-4.
PMID: 27280310
No abstract available.
12.
Turturro S, Najor M, Ruby C, Cobleigh M, Abukhdeir A
Breast Cancer Res Treat
. 2016 Feb;
156(1):33-43.
PMID: 26915040
A review of the literature finds that women diagnosed with breast cancer, who were on an aspirin regimen, experienced a decreased risk of distant metastases and death. Several recent studies...
13.
Siziopikou K, Anderson S, Cobleigh M, Julian T, Arthur D, Zheng P, et al.
Breast Cancer Res Treat
. 2013 Nov;
142(2):415-21.
PMID: 24202240
NSABP B-43 is the first prospective, randomized phase III multi-institution clinical trial targeting high-risk, HER2-positive DCIS. It compares whole breast irradiation alone with WBI given concurrently with trastuzumab in women...
14.
Schneider B, Gray R, Radovich M, Shen F, Vance G, Li L, et al.
Clin Cancer Res
. 2013 Jan;
19(5):1281-9.
PMID: 23340303
Purpose: Clinically validated biomarkers for anti-angiogenesis agents are not available. We have previously reported associations between candidate VEGFA single-nucleotide polymorphisms (SNP) and overall survival (OS) in E2100. The associations between...
15.
Rao R, Cobleigh M
Oncology (Williston Park)
. 2012 Aug;
26(6):541-7, 550, 552 passim.
PMID: 22870539
Endocrine therapy is a critical part of adjuvant therapy in women with hormone receptor-positive breast cancer, and has been shown to reduce the risk of recurrence and death from breast...
16.
Cobleigh M
Semin Oncol
. 2011 May;
38 Suppl 2:S11-6.
PMID: 21600380
Many cytotoxic therapies are available for patients with metastatic breast cancer, but response rates are low and acquired or de novo resistance is virtually universal. Among the agents that are...
17.
Jubb A, Miller K, Rugo H, Harris A, Chen D, Reimann J, et al.
Clin Cancer Res
. 2011 Jan;
17(2):372-81.
PMID: 21224365
Purpose: The addition of bevacizumab to cytotoxic chemotherapy has demonstrated a progression-free survival (PFS) benefit in the first-line and second-line treatment of advanced or metastatic breast cancer (MBC). However, the...
18.
Rao R, Cobleigh M, Gray R, Graham 2nd M, Norton L, Martino S, et al.
Med Oncol
. 2010 Sep;
28 Suppl 1:S39-47.
PMID: 20878269
Fenretinide and tamoxifen have additive antitumor effects preclinically. We performed a randomized, placebo-controlled, double-blind adjuvant trial in breast cancer patients treated for 5 years with tamoxifen, with or without fenretinide....
19.
Taylor M, Haffty B, Rabinovitch R, Arthur D, Halberg F, Strom E, et al.
Int J Radiat Oncol Biol Phys
. 2009 Mar;
73(4):997-1002.
PMID: 19251087
This summary focuses on the role of postoperative radiation therapy in patients treated with modified radical mastectomy for invasive breast cancer, particularly in patients receiving systemic therapy.
20.
Dickler M, Cobleigh M, Miller K, Klein P, Winer E
Breast Cancer Res Treat
. 2008 May;
115(1):115-21.
PMID: 18496750
Purpose: To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines,...